The JAK-inhibitor, JAB/SOCS-1 selectively inhibits cytokine-induced, but not v-Src induced JAK-STAT activation

Oncogene. 2000 Sep 28;19(41):4795-801. doi: 10.1038/sj.onc.1203829.

Abstract

Recently, constitutive activation of JAK kinases (JAKs) and/or signal transducers and activators of transcription (STATs) has been reported in growing numbers of human cancer cells as well as oncogene-transformed cells. JAB/SOCS-1 has been shown to be an intrinsic JAK tyrosine kinase inhibitor and to suppress the cytokine-dependent JAK-STAT pathway. In this report, we investigated the effect of ectopic expression of JAB on v-Src-induced JAK-STAT activation. Forced expression of JAB in v-Src-transformed NIH3T3 cells neither suppressed phosphorylation of STAT3 and JAK1/JAK2 nor blocked STAT3-reporter gene activation. Colony forming assay also showed that JAB did not suppress v-Src-induced transformation of NIH3T3 cells, while dominant negative STAT3 suppressed it. In contrast, JAB could downregulate phosphorylation of STAT1 and STAT3 induced by interferon gamma (IFNgamma) and interleukin-6 (IL-6) plus soluble IL6 receptor (sIL-6R), respectively. Furthermore, in vitro kinase assay indicated that JAB suppressed hyperactivation of JAK1/JAK2 and JAK1 induced by IFNgamma and IL-6 plus sIL-6R respectively, but not v-Src-induced basal JAK1/JAK2 activity. Nevertheless, both JAK1/JAK2 activated by v-Src and that activated by IL-6 plus sIL-6R could similarly bind JAB. These results clearly demonstrate that JAB distinguishes cytokine-induced JAK-STAT signaling from v-Src-induced one and can not suppress the transformation with v-Src.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • 3T3 Cells / drug effects
  • 3T3 Cells / metabolism
  • Acute-Phase Reaction / genetics
  • Amino Acid Substitution
  • Animals
  • Carrier Proteins / pharmacology*
  • DNA-Binding Proteins / genetics
  • DNA-Binding Proteins / metabolism*
  • Dimerization
  • Enzyme Activation / drug effects
  • Genes, Reporter
  • Humans
  • Interferon-gamma / antagonists & inhibitors*
  • Interferon-gamma / pharmacology
  • Interleukin-6 / antagonists & inhibitors*
  • Interleukin-6 / pharmacology
  • Intracellular Signaling Peptides and Proteins*
  • Janus Kinase 1
  • Janus Kinase 2
  • Mice
  • Oncogene Protein pp60(v-src) / physiology*
  • Phosphorylation / drug effects
  • Protein Processing, Post-Translational / drug effects*
  • Protein-Tyrosine Kinases / metabolism*
  • Proto-Oncogene Proteins*
  • Receptors, Interleukin-6 / physiology
  • Regulatory Sequences, Nucleic Acid
  • Repressor Proteins*
  • STAT1 Transcription Factor
  • STAT3 Transcription Factor
  • Signal Transduction / drug effects*
  • Solubility
  • Suppressor of Cytokine Signaling 1 Protein
  • Suppressor of Cytokine Signaling Proteins
  • Trans-Activators / genetics
  • Trans-Activators / metabolism*
  • Transfection

Substances

  • Carrier Proteins
  • DNA-Binding Proteins
  • Interleukin-6
  • Intracellular Signaling Peptides and Proteins
  • Proto-Oncogene Proteins
  • Receptors, Interleukin-6
  • Repressor Proteins
  • SOCS1 protein, human
  • STAT1 Transcription Factor
  • STAT1 protein, human
  • STAT3 Transcription Factor
  • STAT3 protein, human
  • Socs1 protein, mouse
  • Stat1 protein, mouse
  • Stat3 protein, mouse
  • Suppressor of Cytokine Signaling 1 Protein
  • Suppressor of Cytokine Signaling Proteins
  • Trans-Activators
  • Interferon-gamma
  • Protein-Tyrosine Kinases
  • JAK1 protein, human
  • JAK2 protein, human
  • Jak1 protein, mouse
  • Jak2 protein, mouse
  • Janus Kinase 1
  • Janus Kinase 2
  • Oncogene Protein pp60(v-src)